Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination
Luís A. Pérez-Romasanta, Elisabet González-Del Portillo, A. Rodríguez-Gutierrez, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 192-192
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells
Mu Qi, Masoud Najafi
International Immunopharmacology (2021) Vol. 98, pp. 107895-107895
Closed Access | Times Cited: 58
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial
Zhongchao Li, Jing Liu, Bo Zhang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Improving the efficacy of combined radiotherapy and immunotherapy: focusing on the effects of radiosensitivity
Zhiru Gao, Qian Zhao, Yiyue Xu, et al.
Radiation Oncology (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 16
Photosynthetic bacteria-based whole-cell inorganic-biohybrid system for multimodal enhanced tumor radiotherapy
Shiyuan Hua, Jun Zhao, Lin Li, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
The Role of Glutamine Synthetase on the Sensitivity to Radiotherapy of Hepatocellular Carcinoma
Yuan He, Huihan Yu, Yijun Lu, et al.
Radiation Research (2025) Vol. 203, Iss. 3
Closed Access
Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis
Jiaxi Zheng, Minghai Shao, Weifang Yang, et al.
International Immunopharmacology (2022) Vol. 112, pp. 109244-109244
Open Access | Times Cited: 21
Role of palliative SBRT in barcelona clinic liver cancer-stage C hepatocellular carcinoma patients
Deepti Sharma, Deepak Thaper, Rose Kamal, et al.
Strahlentherapie und Onkologie (2023) Vol. 199, Iss. 9, pp. 838-846
Closed Access | Times Cited: 11
Bi/Se-Based Nanotherapeutics Sensitize CT Image-Guided Stereotactic Body Radiotherapy through Reprogramming the Microenvironment of Hepatocellular Carcinoma
Jiani Liu, Jiayao Chen, Hongxing Liu, et al.
ACS Applied Materials & Interfaces (2021) Vol. 13, Iss. 36, pp. 42473-42485
Closed Access | Times Cited: 26
Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial–Mesenchymal Transition and Metastasis
Yueh‐Shan Weng, I‐Tsang Chiang, Jai–Jen Tsai, et al.
International Journal of Radiation Oncology*Biology*Physics (2022) Vol. 115, Iss. 3, pp. 719-732
Open Access | Times Cited: 18
Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations
Adam Hatzidakis, Lukáš Müller, Μiltiadis Krokidis, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2469-2469
Open Access | Times Cited: 16
A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus
Zeyu Zhang, Chan Li, Weijun Liao, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3619-3619
Open Access | Times Cited: 13
Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma
Alireza Tojjari, James Yu, Anwaar Saeed
Cancers (2024) Vol. 16, Iss. 5, pp. 1058-1058
Open Access | Times Cited: 2
BTBD10 is a Prognostic Biomarker Correlated With Immune Infiltration in Hepatocellular Carcinoma
Jianhui Li, Xiaojuan Tian, Ye Nie, et al.
Frontiers in Molecular Biosciences (2022) Vol. 8
Open Access | Times Cited: 10
Verbascoside enhances radiosensitivity of hepatocellular carcinoma cells through regulating miR‐101‐3p/Wee1 axis
Lin Sun, Huangxing Cai, Tengchao Zhou, et al.
Drug Development Research (2022) Vol. 83, Iss. 4, pp. 891-899
Closed Access | Times Cited: 8
Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety
Isaure Roquette, Emilie Bogart, T. Lacornerie, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 3892-3892
Open Access | Times Cited: 8
Intrafractional Diaphragm Variations During Breath-Hold Stereotactic Body Radiotherapy for a Liver Tumor Based on Real-Time Registration Between Kilovoltage Projection Streaming and Digitally Reconstructed Radiograph Images: A Case Report
Atsuto Katano, Yuki Nozawa, Masanari Minamitani, et al.
Cureus (2023)
Open Access | Times Cited: 4
Advances in external beam radiation for hepatocellular carcinoma, stereotactic body radiation therapy (SBRT) and particle therapy
L Seth, Kevin L. Stephans
Hepatoma Research (2024)
Open Access | Times Cited: 1
Application of nanotechnology in the treatment of hepatocellular carcinoma
Liu Cai, Yanyuan Du, Hongtai Xiong, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis
Feng Xian, Jing Wu, Liming Zhong, et al.
Medicine (2023) Vol. 102, Iss. 10, pp. e33204-e33204
Open Access | Times Cited: 3
Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis
Huilin Xu, Pingpo Ming, Zhenyu Zhao, et al.
Integrative Cancer Therapies (2023) Vol. 22
Open Access | Times Cited: 3
X-ray-based cancer diagnosis and treatment methods
Safura Jokar, Saeedeh Khazaei, Hossein Behnammanesh, et al.
Elsevier eBooks (2023), pp. 239-294
Closed Access | Times Cited: 2
Establishment of image‐guided radiotherapy of orthotopic hepatocellular carcinoma mouse model
Kaixiao Zhou, Yabo Jiang, Shuang Feng, et al.
Animal Models and Experimental Medicine (2023) Vol. 6, Iss. 5, pp. 419-426
Open Access | Times Cited: 2
Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic body radiation therapy or systemic therapy alone
Alexander Piening, Anand Swaminath, John Dombrowski, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
Notable-HCC: A phase Ib trial of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with early stage resectable hepatocellular carcinoma
Lei Zhao, Zhongchao Li, Jing Liu, et al.
Research Square (Research Square) (2024)
Open Access
Cancer nanoimmunotherapy in the present scenario
Alejandra Ancira-Cortez, Brenda Gibbens-Bandala, Pedro Cruz-Nova, et al.
Elsevier eBooks (2024), pp. 653-681
Closed Access
Page 1 - Next Page

Scroll to top